RxDoctor Payments Data

Emily McGowan, MD

Allergy & Immunology · Charlottesville, VANPI 1053584532

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Sanofi at 39.6% of the total. 2025 is the largest year on record at $17,526, more than ten times the $4 reported in 2019.

$31,402in general payments, 2019–2025

Across 19 payments — averaging $1652.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$12K
  • Regeneron$7K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • Astrazeneca UK Limited$2K
  • AstraZeneca$1K
  • plus $853 from 1 others
$110,218in research payments, 2019–2025

Across 31 payments — averaging $3555.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$110K

What the payments were for

  • Consulting fees$17,86557%
  • Speaking & faculty fees$12,42040%
  • Travel & lodging$7282%
  • Food & beverage$3901%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,402 in reported general payments places this provider in the 85th percentile of 133 allergy & immunology providers in Virginia.

See all allergy & immunology providers in Virginia

Medicare billing

Part B allowed, 2024
$3,318
Medicare patients
27
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab20$73,087

Paid to pharmacies, not to this prescriber.

Other allergy & immunology in Charlottesville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →